EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease

Ioanna Alefanti, Christos Koros iD, Viktoria Tsami, Athina Maria Simitsi, Chrisoula Kartanou, Nikolaos Papagiannakis, Maria Bozi, Roubina Antonelou, Matina Maniati, Ann-Kathrin Hauser, Stefanos Varvaressos, Anastasios Bonakis und 9 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.16562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Ioanna Alefanti und 20 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hellenic General Secretariat for Research and Innovation (GSRI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The p.A53T variant in the SNCA gene was considered, until recently, to be the only SNCA variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) SNCA pathogenic variant in five affected individuals of three Greek families, leading to autosomal dominant PD. This study aims to further explore the presence and phenotypic expression of this variant in the Greek PD population.

Methods

Restriction fragment length polymorphism (RFLPs) was used for genotyping of 664 Greek PD cases. Detailed clinical information was obtained for the carriers and p.A30G‐positive samples underwent haplotype analysis.

Results

We identified 10 additional p.A30G‐positive PD patients (1.5%), of whom 4 were sporadic cases (0.9%). They manifested typical Parkinsonian motor dysfunction, with a mean age of onset of 51.7 years (range: 33–62) and a broad spectrum of non‐motor symptoms. The absence of affected first degree relatives in four out of ten index cases, and the presence of a phenocopy in an additional family, suggest that the p.A30G variant manifests reduced penetrance. The common haplotype among the p.A30G carriers confirmed a founder effect. Furthermore, two asymptomatic carriers were identified, with possible premotor manifestations.

Conclusions

These findings underscore that the p.A30G SNCA pathogenic variant represents an important, albeit rare, cause of genetic PD in the Greek population. This is the first time in which a genetic synucleinopathy, with a variant in the SNCA gene, is clearly linked to an appreciable frequency of sporadic PD in a particular population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseGenetic Predisposition to DiseaseHumansGreeceMaleMiddle AgedFemaleAdultPedigreeHaplotypes

Stichwörter der Autor:innen

SNCAGreek populationParkinson's diseasep.A30G

Substanzen

alpha-SynucleinSNCA protein, human

Autor:innen und Institutionen

  • 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Neurogenetics Unit, 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Laboratory of Neurodegenerative Diseases, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
  • 2nd Department of Neurology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen and German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Department of Medical Genetics, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Christos Koros

Förderung

  • Hellenic General Secretariat for Research and Innovation (GSRI)

Zitieren

APA

Alefanti, I., Koros, C., Tsami, V., Simitsi, A. M., Kartanou, C., Papagiannakis, N., Bozi, M., Antonelou, R., Maniati, M., Hauser, A. K., Varvaressos, S., Bonakis, A., Lourentzos, K., Makrythanasis, P., Papageorgiou, S. G., Proukakis, C., Potagas, C., Gasser, T., Koutsis, G., …, & Stefanis, L. (2025). The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. European Journal of Neurology. https://doi.org/10.1111/ene.16562

Vancouver

Alefanti I, Koros C, Tsami V, Simitsi AM, Kartanou C, Papagiannakis N, et al. The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. European Journal of Neurology. 2025. doi:10.1111/ene.16562

BibTeX
@article{Alefanti2025,
  author = {Alefanti, Ioanna and Koros, Christos and Tsami, Viktoria and Simitsi, Athina Maria and Kartanou, Chrisoula and Papagiannakis, Nikolaos and Bozi, Maria and Antonelou, Roubina and Maniati, Matina and Hauser, Ann-Kathrin and Varvaressos, Stefanos and Bonakis, Anastasios and Lourentzos, Konstantinos and Makrythanasis, Periklis and Papageorgiou, Sokratis G and Proukakis, Christos and Potagas, Constantinos and Gasser, Thomas and Koutsis, Georgios and Karadima, Georgia and Stefanis, Leonidas},
  title = {The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.16562}
}
Kostenlos starten →